CSPC Pharmaceutical Group (01093): 8 latest clinical trial advances to be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress

Zhitong Finance APP News, CSPC Pharmaceutical Group (01093) announced that the Group will present 8 latest clinical trial advances at the European Society for Medical Oncology (ESMO) Annual Congress to be held in Madrid, Spain, from October 23 to October 27, 2026, of which 2 were selected as Late-breaking Abstracts (LBA). The 8 clinical advances selected this time will be presented in the form of 1 preferred oral presentation, 3 rapid oral presentations, 3 posters, and 1 e-poster, covering tumor types such as breast cancer, lung cancer, gastric cancer, liver cancer, colon cancer, pancreatic cancer, and perivascular epithelioid cell tumor, fully demonstrating the Group's R&D strength and clinical research capabilities in the field of oncology treatment.